MedTrace Logo

A Predictive Model for Recurrence of Colorectal Cancer Based on Multi-omics of Portal Vein Blood

NCT06524245 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2024-07-31

No results posted yet for this study

Summary

This multi-center study aims to develop a precise predictive model for colorectal cancer (CRC) recurrence and metastasis based on multi-omics analysis of portal vein blood. Despite advances in surgical treatments, approximately 40% of CRC patients experience tumor recurrence or metastasis post-surgery, with 80-90% of metastases being unresectable. The study will include stage I-IV CRC patients and will be conducted in two phases: a nested case-control study and a bidirectional cohort study. Comprehensive multi-omics sequencing will be performed on samples from primary tumors, adjacent tissues, normal intestinal tissues, portal vein blood, and peripheral blood. The goal is to identify specific biomarkers in the portal vein and peripheral blood associated with CRC recurrence and metastasis, and to compare the predictive accuracy of models based on these biomarkers. The ultimate objective is to provide a more effective method for early prediction and intervention of CRC recurrence and metastasis, thereby improving patient outcomes.

Project Information:

Project Title: A predictive model for recurrence of colorectal cancer based on multi-omics of portal vein blood: a multi-center study Project Duration: January 2020 to December 2026 Lead Institution: Peking University Shougang Hospital Principal Investigator: Gu Jin Contact: Hong Haopeng, [email protected]

Conditions

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    collaborator OTHER

  • Peking University Third Hospital

    collaborator OTHER

  • Peking University First Hospital

    collaborator OTHER

  • Chinese PLA General Hospital

    collaborator OTHER

  • Peking University Shougang Hospital

    lead OTHER

Principal Investigators

  • Jin Gu, Prof. · Peking University Shougang Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06524245 on ClinicalTrials.gov